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LETTERS TO THE EDITOR
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fRegarding “Endoluminal treatment of type IA
endoleak with Onyx”
We read with great interest the article by Grisafi et al1 recently
published in the Journal of Vascular Surgery that reported effec-
tiveness of selective arterial embolization using Onyx in a patient
with type IA endoleak after endovascular abdominal aortic aneu-
rysm repair. We have several comments. First of all, we would like
to congratulate the authors for their case, which represents the first
one to date reporting results on transarterial embolotherapy with
Onyx as an embolic agent in such a setting. However, the only
available data on the use of this embolic material for peripheral
applications come from case reports. Indeed, Onyx is a new liquid
embolic agent composed of ethylene-vinyl alcohol copolymer dis-
solved in dimethyl sulphoxide (DMSO), with emerging applica-
tions in neurovascular procedures, predominantly embolization of
cerebral aneurysms and arteriovenous malformations.2 The main
advantages of Onyx are its nonadhesive properties, high radiopac-
ity, and long solidification periods, which, compared with acrylic
glues, make the embolization procedure more controllable and
predictable.3 Nevertheless, the authors did not bring to attention
in detail several important disadvantageous characteristics of the
use of Onyx. First, DMSO can cause severe vasospasm if injected
rapidly. This is most likely to occur early in the procedure and can
be avoided by using no more than 0.2 mL of DMSO in the first
minute of injection. In this case, the authors used a total of six vials
of Onyx, but did not report the total injection time of DMSO and
Onyx for their procedure. In our experience, the duration of
injection can be time-consuming and varies depending on the
amount of Onyx used. Secondly, DMSO is volatile and is excreted
via respiration and sweat. This has a typical smell not unlike that of
diabetic ketoacidosis and may last a few days. The patient and ward
staff should be warned to expect this. Lastly, the use of Onyx has
cost implications, as it is much more expensive than alternative
embolic materials, and it requires specific DMSO-compatible mi-
crocatheters. The prohibitive costs of using Onyx have led to its
restricted use in neuroradiology in most of the institutions
around the world. Then, we suggest an alternative conservative
therapeutic option when correction of the type IA endoleak by
securing the attachment site with balloon angioplasty or stent
graft extension is impossible or unsuccessful,4 especially because
of the proximity of visceral arteries ostia. Indeed, selective
transarterial catheterization of the endoleak throughout proxi-
mal uncovered meshes of the stent and release of detachable
microcoils into the nidus can be successfully attempted, as we
recently reported.5 The remodeling technique using an intra-
aortic balloon catheter, initially developed for the treatment of
wide-necked intracranial aneurysms,6 is then needed in order to
stabilize the microcatheter and allow precise and safe deposition
of the microcoils against the aneurysmal wall, limiting the risk of
malposition or migration.5
In conclusion, we think the use of Onyx as an embolic agent is
very promising, but the important cost aspect needs to be borne in
mind when there are other cheaper alternatives that would be as
effective.
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We would like to thank Loffroy and Steinmetz for sharing
heir thoughts about the use of Onyx in the treatment of type IA
ndoleaks after endovascular aneurysm repair. They point out
everal key disadvantages of this embolic agent, and we agree with
heir characterization. As such, we inform all patients of the
haracteristic smell associated with the elimination of dimethyl
ulfoxide prior to treatment. This side effect is remarkably well
olerated, and we have received few complaints.
The potential for vasospasm is also well recognized. This
erves to emphasize the need for appropriate training of practi-
ioners in the use of this product. While vasospasm is of particular
oncern in the cerebrovasculature, our experience with treating en-
oleaks after endovascular aneurysm repair suggests the occurrence to
e infrequent. Our belief is that accurate placement of the microcath-
ter delivery system at the nidus in the aneurysm neck is important in
reventing vasospasm. As a result, we have avoided protracted injec-
ion times.
The cost implications of the agent may be high; however, this
hould be balanced against the cost of management of a ruptured
bdominal aortic aneurysm. Loffroy and Steinmetz suggest the
emodeling technique as a cost-effective alternative, yet the ex-
ense of this technique is not trivial. Further, coils may prove
isadvantageous when delivery to inaccessible endoleak outflow
hannels is desired. With Onyx, flow dynamics may be exploited to
each these targets.
The population of patients with type IA endoleaks at high risk
or open conversion is gratifyingly small. Unfortunately, our ability
o determine the optimal treatment strategy is hampered as a
esult. More study is needed to determine which endovascular
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